NCT02530463View on ClinicalTrials.gov

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

September 8, 2015

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome
Interventions
DRUG

Azacitidine

Given IV

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER